American CryoStem to Present at National Investment Banking Association's 126th Investment Conference

Eatontown, New Jersey, UNITED STATES

EATONTOWN, N.J., June 4, 2013 (GLOBE NEWSWIRE) -- American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at the National Investment Banking Association's (NIBA) 126th Investment Conference to be held in New York City, June 17-19, 2013.

John Arnone, CEO commented, "Now that our cutting-edge products are ready for commercialization after years of research and development, presenting at the NIBA Investment Conference will provide American CryoStem the platform to display its proprietary adipose derived stem cell technologies. This will be the Company's first public financial presentation, we look forward to developing strong financial alliances to continue the growth of our business model and expand our sales and marketing efforts as the Regenerative Medicine Industry takes hold globally."

NIBA is a national not-for-profit trade association of regional and independent brokerages, investment banking firms, institutional investors and related capital market service providers. Since its inception, NIBA member firms have successfully completed over 1000 equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8800 registered representatives with an estimated $78 billion in assets under management, and are responsible for 90% of all Initial Public Offerings under $20 million.

NIBA conferences provide a venue for invited companies to share meaningful insight into their business operations, short and long-term growth strategies and industry vision, and give its members the opportunity to exchange ideas and information, evaluate presentations made by public and private companies seeking capital or exposure, collectively voice their positions on issues impacting the securities industry, and enhance their knowledge and expertise through ongoing education programs designed to enable them to remain competitive in today's financial market.


WHO: John Arnone – Chairman and CEO
  Anthony Dudzinski – COO 
WHEN:  June 17 – 19, 2013
WHERE:  New York Marriott Downtown
  85 West Street at Albany Street
  New York, New York

About American CryoStem Corporation

A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage, cell culture and differentiation media development facility in Mount Laurel, New Jersey. For more information, please visit and